<DOC>
	<DOCNO>NCT02187809</DOCNO>
	<brief_summary>To investigate long-term safety tolerability clobazam administer 1 year adjunctive therapy paediatric patient age ≥1 ≤16 year Dravet Syndrome .</brief_summary>
	<brief_title>Safety Tolerability Clobazam Adjunctive Therapy Paediatric Patients Aged ≥1 ≤16 Years With Dravet Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Clobazam</mesh_term>
	<criteria>The inclusion exclusion criterion patient participate leadin Study 14362A transfer 14362A study patient participate leadin Study 14362A inclusion/exclusion separately list . 1 . The patient diagnosis Dravet Syndrome support : 1. onset seizure first year life 2. history feverinduced prolonged seizure determine Investigator may include prolonged ( approximately 15 minute longer ) hemiclonic seizures 3. multiple seizure type may include : generalise tonicclonic ( required inclusion ) clonic ( require inclusion ) myoclonic jerks/seizures 4. history normal development prior seizure onset follow development delay regression seizure onset 5. abnormal EEG consistent Dravet Syndrome 2 . The patient currently receive stable dose clobazam least 0.5 mg/kg/day ( maximum 20 mg/day ) least 3 month Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>